Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies targeting chronic kidney disease (CKD) to significantly improve patient health outcomes. Founded in 2007 and headquartered in Cambridge, US, Akebia Therapeutics is focused on developing treatments for CKD. The company underwent a significant merger with Keryx Biopharmaceuticals in 2018 and has raised USD 132.

00 mn in its most recent funding round on May 11, 2020, bringing its total amount raised to USD 132. 00 mn. The company's CEO is John Butler. Akebia Therapeutics is a fully integrated biopharmaceutical company that offers two FDA-approved products designed to improve outcomes for individuals suffering from chronic kidney disease (CKD).

These therapies focus on enhancing kidney function and minimizing the need for dialysis, targeting healthcare providers, nephrologists, hospitals, and clinics across the United States and other regions. In the most recent fiscal year of 2024, Akebia Therapeutics reported a revenue of USD 160. 18 mn with an EBITDA of USD -8. 77 mn.

The company generates revenue through direct sales of its pharmaceutical products to healthcare providers and facilities, capitalizing on a sustainable demand for kidney disease management solutions within the healthcare sector. Akebia Therapeutics plans to leverage its recent funding to support ongoing development of new therapeutic solutions for CKD. The company aims to expand its reach into international markets with targeted growth planned through 2025. This strategic growth initiative follows the successful raising of USD 132.

00 mn in May 2020, which will enable further investments in product innovation and market expansion.